ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Entry into a Material Definitive Agreement

ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

Story continues below

On October 4, 2017, Adamas Pharma, LLC (“Adamas”), a wholly-owned subsidiary of Adamas Pharmaceuticals, Inc., entered into an Amended and Restated API Supply Agreement (the “Agreement”) with Moehs Ibérica, S.L. (“Moehs”). to the Agreement, Moehs will supply to Adamas Amantadine HCl, the active pharmaceutical ingredient (“API”) in Adamas’s product GOCOVRITM (amantadine) extended-release capsules, formerly referred to as ADS-5102, for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Under the terms of the Agreement, Adamas will provide Moehs with forecasts and purchase orders for quantities of API, and Moehs will supply Adamas with API, subject to inspection and acceptance by Adamas and the other terms of the agreement, including payment of the purchase price. Each party will indemnify the other party for (a) liabilities, expenses or costs incurred by the other party arising out of the negligent or intentionally wrongful acts or omissions of the indemnifying party or (b) a breach by the indemnifying party of its covenants, obligations, representations or warranties made or undertaken by the indemnifying party under the Agreement, in each case subject to certain requirements set forth in the Agreement.

The Agreement has a term of 14 years, and may be terminated by either party for breach, may be terminated by Adamas upon 180 days prior written notice, and may be terminated by Moehs upon three years’ prior written notice.


About ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

An ad to help with our costs